SMS Pharmaceuticals share news, announcements and annual reports
NSE: SMSPHARMABSE: 532815Pharmaceuticals & BiotechnologySmall Cap
SMS Pharmaceuticals Limited · Face value ₹1 Face value. The nominal value of one share as the company issued it, the unit its share capital is counted in and a dividend can be stated as a percentage of; it has no link to the share price. Face value in the glossary · Listed Feb 2007
Last close ₹504.15down ₹7.20 (1.41%)BSE ₹504.25
Share price at the NSE close on 2 Nov 2026. Previous close ₹511.35.
2 Nov: open ₹511.00, high ₹514.80, low ₹471.25
52-week range of traded prices to 2 Nov 2026
₹270.10Low, 24 Nov 2025₹525.00High, 30 Oct 2026
- Next results date: the board meets on 4 Nov 2026 to consider: financial results. The notice · Results calendar
- Market capMarket capitalisation. Share price times the number of shares: what the whole company is worth at the day's price. The rank is by average market value over the six months to Jun 2026, among listed companies. Market capitalisation: how it is worked out
- ₹4,721 Cr920th largest listed
- P/EPrice to earnings, trailing. Market cap divided by the profit of the last twelve months (the latest four quarters, or two half years for a company that reports half-yearly) that belongs to the company's own shareholders, after the share of the other owners of its subsidiaries: what investors pay for each rupee of a year's profit. Price to earnings, trailing: how it is worked out
- 45.98
- P/BPrice to book. Market cap divided by the net worth that belongs to the company's own shareholders, its assets less everything it owes and less the other owners' share of its subsidiaries, on its latest balance sheet. Price to book: how it is worked out
- 6.01
- Dividend yieldDividend yield. Dividends paid per share in the twelve months to the day, as a percentage of the day's share price.
- 0.08%
- ROEReturn on equity. Profit over the last twelve months (the latest four quarters, or two half years for a company that reports half-yearly) that belongs to the company's own shareholders, as a percentage of their net worth, the money they have in the business. Net worth is the average of the latest balance sheet and the one a year before it.
- 14.4%
- ROCEReturn on capital employed. Operating profit after depreciation (revenue less operating expenses and depreciation, without other income and one-off items) as a percentage of all the money the business runs on: the whole group's net worth, the other owners of its subsidiaries included, plus borrowings. Lease liabilities are not counted: the results filings do not state them. The profit is over the last twelve months (the latest four quarters, or two half years for a company that reports half-yearly); net worth and borrowings are on the latest balance sheet.
- 11.5%
- Debt to equityDebt to equity. Borrowings divided by the whole group's net worth, the other owners of its subsidiaries included: rupees borrowed for each rupee of equity in the business. Lease liabilities are not counted: the results filings do not state them. From the balance sheet at the end of Mar 2026.
- 0.46
- Volume, NSEVolume. Shares traded on the last trading day. Volume in the glossary
- 8,24,268
SMS Pharmaceuticals share news and announcements
718 announcements, routine notices left out, newest first. Page 11 of 15.
Mar 2016
Feb 2016
12 Feb · Board meeting
Out come of the Board Meeting
Jan 2016
Dec 2015
24 Dec · Business
7 Dec · Corporate action
Company has fixed Record Date as December 18, 2015 for the purpose of ascertaining the list of shareholders eligible for stock split.
Nov 2015
4 Nov · Meeting
Oct 2015
9 Oct · Board meeting
Sep 2015
30 Sep · Disclosure of Voting Pattern - Clause 35A
30 Sep · Dividend
Declare dividend of Rs. 2/- on each shares of Rs. 10/- for the financial year 2014-15 in Annual General Meeting.
Aug 2015
8 Aug · Board meeting
Jul 2015
Jun 2015
9 Jun · Code of Conduct under SEBI(PIT) Reg., 2015
1 Jun · Code of Conduct under SEBI(PIT) Reg., 2015
Board of the Company at its meeting held on May 30, 2015 has Approved the Code of Practices and Procedures for Fair Disclosure of Un published Price Sensitive Information formulated pursuant to the provisions of Regulation 8 ofSEBI (Prohibition of Insider Trading) Regulations, 2015.
May 2015
Apr 2015
Feb 2015
6 Feb · Board meeting
Board of Directors of the Company at their meeting held on February 06, 2015 has appointed an Independent Committee to explore the possibilities of Demerger of Non-FDA Manufacturing Units of the Company and submit a detailed report to the Board for consideration.
Jan 2015
27 Jan · Board meeting
Interalia, to consider the Un-audited Financial Results of the Company for the Quarter ended December 31, 2014 with limited review report.
Nov 2014
27 Nov · Updates
Exchange has sought clarification from SMS Pharmaceuticals Limited with respect to a press release dated November 27, 2014 regarding the settlement of legal disputes between the Company and M/s. Natco Pharma Limited. In this regard, the Exchange has advised the Company to provide clarification/confirmation with respect to the following: (1) Brief details of litigation viz. name(s) of the court/tribunal/agency where litigation is filed, brief details of dispute/litigation. The response from the Company is awaited.27 Nov · Updates
Legal disputes between the Company and M/s.Natco Pharma Limited have been amicably settled. Out of the settlement, the company has received a sum of Rs.15.07 crores from M/s.Natco Pharma Limited apart from the balance principal amount receivable from the respective courts.